Compare Amphastar Pharmaceuticals Inc (AMPH) vs Ishares Msci Brazil ETF (EWZ) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

EWZ trades at $35.93, up 2.77% with a bullish technical signal supported by moving averages. The ETF has gained approximately 11% year-to-date, benefiting from Brazil's monetary easing cycle and commodity strength. Recent news highlights Brazil's $9.92 billion Eco Invest auction and export adjustments to meet EU requirements, supporting economic growth prospects.

Outlook remains positive with asymmetric upside from Brazil's rate-cutting cycle and commodity tailwinds, though concentrated exposure to Petrobras and Vale creates dividend inconsistency risk. The ETF trades at a discount to emerging market peers with 9.6x forward P/E, offering value if Brazil's economic reforms continue.